1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

18 Sep 2023
Admin
News Article

AstraZeneca and Daiichi Sankyo Recommend for Approval of Enhertu

Enhertu, developed jointly by AstraZeneca and Daiichi Sankyo, has received a recommendation for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC).

This recommendation applies to patients whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.

Enhertu is a specifically engineered antibody-drug conjugate (ADC) directed at HER2. It comprises a HER2 monoclonal antibody linked to a topoisomerase I inhibitor payload, which is an exatecan derivative. This linkage is achieved through a stable tetrapeptide-based cleavable linker.

In the clinical trial, Enhertu administered at a dose of 5.4mg/kg exhibited a confirmed objective response rate (ORR) of 49.0 percent (with a 95 percent confidence interval [CI] ranging from 39.0 to 59.1 percent) and a disease control rate (DCR) of 93.1 percent in patients who had previously received treatment for advanced or metastatic HER2-mutant (HER2m) non-small cell lung cancer (NSCLC).

Previously, Enhertu had received approval in more than 50 countries for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer. These patients had received one or more prior anti-HER2-based regimens, either in the metastatic setting, or in the neoadjuvant or adjuvant setting, and had developed disease recurrence during or within six months of completing therapy.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!